Sellas Life Sciences Group Inc
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or … Read more
Sellas Life Sciences Group Inc (SLS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.155x
Based on the latest financial reports, Sellas Life Sciences Group Inc (SLS) has a cash flow conversion efficiency ratio of -0.155x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.07 Million) by net assets ($45.63 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sellas Life Sciences Group Inc - Cash Flow Conversion Efficiency Trend (2007–2024)
This chart illustrates how Sellas Life Sciences Group Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Sellas Life Sciences Group Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sellas Life Sciences Group Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GCM Grosvenor Inc
NASDAQ:GCMG
|
0.223x |
|
Thungela Resources Limited
PINK:TNGRF
|
0.049x |
|
CJ Korea Express
KO:000120
|
0.076x |
|
AMERISAFE Inc
NASDAQ:AMSF
|
0.009x |
|
WealthNavi Inc
PINK:WNAVF
|
0.002x |
|
Zhongtong Bus Holding Co Ltd
SHE:000957
|
0.118x |
|
Hubei Zhongyi Science Technology Co. Ltd.
SHE:301150
|
0.004x |
|
Yijiahe Technology Co Ltd
SHG:603666
|
-0.030x |
Annual Cash Flow Conversion Efficiency for Sellas Life Sciences Group Inc (2007–2024)
The table below shows the annual cash flow conversion efficiency of Sellas Life Sciences Group Inc from 2007 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $9.46 Million | $-35.40 Million | -3.740x | -194.98% |
| 2023-12-31 | $-7.98 Million | $-31.41 Million | 3.938x | +180.24% |
| 2022-12-31 | $4.85 Million | $-23.81 Million | -4.908x | -283.78% |
| 2021-12-31 | $20.35 Million | $-26.02 Million | -1.279x | -243.27% |
| 2020-12-31 | $27.96 Million | $-10.42 Million | -0.373x | +87.13% |
| 2019-12-31 | $6.09 Million | $-17.64 Million | -2.896x | +50.08% |
| 2018-12-31 | $5.25 Million | $-30.42 Million | -5.800x | -9.26% |
| 2017-12-31 | $2.07 Million | $-10.99 Million | -5.309x | -238.71% |
| 2016-12-31 | $28.66 Million | $-44.91 Million | -1.567x | +56.02% |
| 2015-12-31 | $13.51 Million | $-48.16 Million | -3.564x | -208.10% |
| 2014-12-31 | $37.06 Million | $-42.87 Million | -1.157x | +76.45% |
| 2013-12-31 | $5.89 Million | $-28.91 Million | -4.911x | -550.28% |
| 2012-12-31 | $27.76 Million | $-20.96 Million | -0.755x | +47.93% |
| 2011-12-31 | $10.11 Million | $-14.67 Million | -1.451x | +65.63% |
| 2010-12-31 | $2.43 Million | $-10.26 Million | -4.221x | +73.42% |
| 2009-12-31 | $741.00K | $-11.77 Million | -15.883x | -1410.61% |
| 2008-12-31 | $8.97 Million | $-9.43 Million | -1.051x | -88.18% |
| 2007-12-31 | $10.82 Million | $-6.05 Million | -0.559x | -- |